Impact of hypoglycemia at the time of hospitalization for heart failure from emergency department on major adverse cardiovascular events in patients with and without type 2 diabetes | Cardiovascular Diabetology | Full Text
Diagnostics | Free Full-Text | miR-146a-5p, miR-223-3p and miR-142-3p as Potential Predictors of Major Adverse Cardiac Events in Young Patients with Acute ST Elevation Myocardial Infarction—Added Value over Left Ventricular Myocardial Work
Cardiovascular outcomes that will change diabetes practice: What are the key findings from recent trials? Prof. Mark Cooper, MD
3P-MACE by baseline covariates. The Forest plot shows hazard ratios... | Download Scientific Diagram
Risk factors and goal achievement related to 3P-MACE. | Download Scientific Diagram
Abbreviations 3P-MACE: 3-point major adverse cardiovascular events;... | Download Scientific Diagram
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. - Abstract - Europe PMC
Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clini
Pharmedu
Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials | Cardiovascular Diabetology | Full Text
A population‐adjusted indirect comparison of cardiovascular benefits of once‐weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease - Evans - 2021 -
Cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in Asians with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials - ScienceDirect
藥學雜誌電子報146期
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high ...
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy CREDENCE Trial | PDF | Chronic Kidney Disease | Renal Function
CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle - ScienceDirect
Alfonso Valle on X: "Efficacy & safety of SGLT2i/GLP-1RA for CV outcomes: meta-analysis 👥 170930 👉GLP-1RA & SGLT2i ⤵️11% 3P-MACE vs placebo/DPP-4 👉SGLT2i vs GLP-1RA ⛔️difference in 3P-MACE SGLT2i ⤵️ 24% HF🏥
Endocrinologist Perspective
Study flow chart. (Abbreviation: 3P-MACE, three point major adverse... | Download Scientific Diagram
3P-MACE by baseline CVD history. The forest plot shows hazard ratios... | Download Scientific Diagram
EMPRISE study outcomes of interest. 3P‐MACE: three‐point major... | Download Scientific Diagram
